Search

Your search keyword '"Shaffer, Brian"' showing total 1,487 results
Start Over Author "Shaffer, Brian"
1,487 results on '"Shaffer, Brian"'

16. Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical Trial.

Author

Shaw, Bronwen, Jimenez-Jimenez, Antonio, Burns, Linda, Logan, Brent, Khimani, Farhad, Shaffer, Brian, Shah, Nirav, Mussetter, Alisha, Tang, Xiao-Ying, McCarty, John, Alavi, Asif, Farhadfar, Nosha, Jamieson, Katarzyna, Hardy, Nancy, Choe, Hannah, Ambinder, Richard, Anasetti, Claudio, Perales, Miguel-Angel, Spellman, Stephen, Howard, Alan, Luznik, Leo, Norkin, Maxim, Pidala, Joseph, Ratanatharathorn, Voravit, Confer, Dennis, Devine, Steven, Horowitz, Mary, Bolaños-Meade, Javier, and Komanduri, Krishna

Subjects
HLA, Hematopoietic cell transplant, Mismatched unrelated donor, Post transplant cyclophosphamide, Humans, Bone Marrow, Follow-Up Studies, Prospective Studies, Cyclophosphamide, Graft vs Host Disease, Unrelated Donors, Recurrence
Abstract

The use of post-transplantation cyclophosphamide (PTCy) as graft-versus-host disease (GVHD) prophylaxis has resulted in reductions in GVHD and improved outcomes in allogeneic hematopoietic cell transplantation (HCT) using HLA-mismatched related donors. We report the 3-year outcomes of the first multicenter prospective clinical trial using PTCy in the setting of mismatched unrelated donor (MMUD) bone marrow HCT. The study enrolled 80 patients, treated with either myeloablative conditioning (MAC; n = 40) or reduced-intensity conditioning (RIC; n = 40), with the primary endpoint of 1-year overall survival (OS). The median follow-up for this study was 34 months (range, 12 to 46 months) in the RIC group and 36 months (range, 18 to 49 months) in the MAC group. Three-year OS and nonrelapse mortality were 70% and 15%, respectively, in the RIC group and 62% and 10% in the MAC group. No GVHD was reported after 1 year. The incidence of relapse was 29% in the RIC group and 51% in the MAC group. OS did not differ based on HLA match grade (63% in the 7/8 strata and 71% in the 4 to 6/8 strata). These encouraging outcomes, which were sustained for 3 years post-HCT, support the continued exploration of MMUD HCT using a PTCy platform. Important future areas to address include relapse reduction and furthering our understanding of optimal donor selection based on HLA and non-HLA factors.

Published
2023

19. Artificial intelligence enabled interpretation of ECG images to predict hematopoietic cell transplantation toxicity

Author

Shaffer, Brian C., Brown, Samantha, Chinapen, Stephanie, Mangold, Kathryn E., Lahoud, Oscar, Lopez-Jimenez, Francisco, Schaffer, Wendy, Liu, Jennifer, Giralt, Sergio, Devlin, Sean, Shah, Gunjan, Scordo, Michael, Papadopoulos, Esperanza, Landau, Heather, Usmani, Saad, Perales, Miguel-Angel, Friedman, Paul A., Gersh, Bernard J., Attia, Itzhak Zachi, Noseworthy, Peter A., and Kosmidou, Ioanna

Published
2024
Full Text
View/download PDF

21. Improved GRFS after posttransplant cyclophosphamide-based vs ATG-based HLA-mismatched unrelated donor transplant

Author

Jimenez, Antonio Jimenez, Komanduri, Krishna, Brown, Samantha, Wang, Trent, Pereira, Denise, Goodman, Mark, Beitinjaneh, Amer, Lekakis, Lazaros, Chinapen, Stephanie, Devlin, Sean, Ponce, Doris, Sauter, Craig, Perales, Miguel-Angel, and Shaffer, Brian C

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Immunology, Clinical Research, Clinical Trials and Supportive Activities, Transplantation, Cancer, Prevention, Hematology, Good Health and Well Being, Antilymphocyte Serum, Cyclophosphamide, Graft vs Host Disease, Humans, Methotrexate, Prospective Studies, Tacrolimus, Unrelated Donors, Cardiovascular medicine and haematology
Abstract

A common method to prevent graft-versus-host disease after allogeneic hematopoietic cell transplantation (HCT) from an HLA-mismatched unrelated donor (MMUD) is tacrolimus, methotrexate, and antithymocyte globulin (ATG). The use of posttransplant cyclophosphamide (PTCy) showed promise in a prospective trial for MMUD HCT. We compared 1-year graft-versus-host disease-free, relapse-free survival (GRFS) in 128 recipients of prophylaxis based on tacrolimus/methotrexate/ATG (ATG group, n = 46) vs PTCy, mycophenolate mofetil, and tacrolimus or sirolimus (PTCy group, n = 82) after MMUD HCT. Patients receiving HCT from a MMUD mismatched at ≥1 locus among HLA-A, HLA-B, HLA-C, and HLA-DRB1 were included. The 2 groups were well matched for HCT indication, high-risk disease, and HCT comorbidity index, whereas more patients on PTCy received bone marrow (50% vs 26%; P = .01) and >1 locus HLA-mismatched (30.5% vs 2.2%; P = .001) grafts. The 1-year GRFS was 16% (95% confidence interval (CI): 8%-31%) vs 54% (95% CI: 44%-66%; P < .001) in the ATG and PTCy groups, respectively. The multivariable adjusted hazard ratio for GRFS was 0.34 (95% CI: 0.21-0.55; P < .001) with the use of PTCy. The 1-year overall survival in the ATG group was 45% (95% CI: 32%-62%) vs 75% (95% CI: 66%-85%) in the PTCy group (P < .001). Relapse incidence was similar. One-year nonrelapse mortality was greater after ATG-based prophylaxis: 38% (95% CI: 23%-52%) vs 16% (95 CI: 9%-25%), P < .001. In summary, PTCy-based prophylaxis resulted in superior GRFS and overall survival in recipients of MMUD.

Published
2022

22. High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease prevention

Author

Holtzman, Noa G., Curtis, Lauren M., Salit, Rachel B., Shaffer, Brian C., Pirsl, Filip, Ostojic, Alen, Steinberg, Seth M., Schulz, Eduard, Wilder, Jennifer S., Hughes, Thomas E., Rose, Jeremy, Memon, Sarfraz, Korngold, Robert, Gea-Banacloche, Juan C., Fowler, Daniel H., Hakim, Frances T., Gress, Ronald E., Bishop, Michael R., and Pavletic, Steven Z.

Published
2024
Full Text
View/download PDF

27. National Marrow Donor Program–Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide

Author

Shaw, Bronwen E, Jimenez-Jimenez, Antonio Martin, Burns, Linda J, Logan, Brent R, Khimani, Farhad, Shaffer, Brian C, Shah, Nirav N, Mussetter, Alisha, Tang, Xiao-Ying, McCarty, John M, Alavi, Asif, Farhadfar, Nosha, Jamieson, Katarzyna, Hardy, Nancy M, Choe, Hannah, Ambinder, Richard F, Anasetti, Claudio, Perales, Miguel-Angel, Spellman, Stephen R, Howard, Alan, Komanduri, Krishna V, Luznik, Leo, Norkin, Maxim, Pidala, Joseph A, Ratanatharathorn, Voravit, Confer, Dennis L, Devine, Steven M, Horowitz, Mary M, and Bolaños-Meade, Javier

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Immunology, Transplantation, Clinical Trials and Supportive Activities, Hematology, Rare Diseases, Clinical Research, Regenerative Medicine, Good Health and Well Being, Adolescent, Adult, Aged, Cyclophosphamide, Female, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Lymphoma, Male, Medically Underserved Area, Middle Aged, Minority Groups, Myelodysplastic Syndromes, Prospective Studies, Registries, Transplantation Conditioning, Unrelated Donors, Young Adult, Oncology and Carcinogenesis, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposeHematopoietic cell transplantation (HCT) is curative for hematologic disorders, but outcomes are historically inferior when using HLA-mismatched donors. Despite unrelated donor registries listing > 38 million volunteers, 25%-80% of US patients lack an HLA-matched unrelated donor, with significant disparity across ethnic groups. We hypothesized that HCT with a mismatched unrelated donor (MMUD) using post-transplant cyclophosphamide (PTCy), a novel strategy successful in overcoming genetic disparity using mismatched related donors, would be feasible and increase access to HCT.Patients and methodsWe performed a prospective phase II study of MMUD bone marrow HCT with PTCy for patients with hematologic malignancies. The primary end point was 1-year overall survival (OS), hypothesized to be 65% or better. 80 patients enrolled at 11 US transplant centers (December 2016-March 2019). Following myeloablative or reduced-intensity conditioning-based HCT, patients received PTCy on days +3, +4, with sirolimus and mycophenolate mofetil starting on day +5. We compared outcomes to Center for International Blood and Marrow Transplant Research contemporary controls receiving PTCy.ResultsNotably, 48% of patients enrolled were ethnic minorities. 39% of pairs were matched for 4-6 out of 8 HLA alleles. The primary end point was met, with 1-year OS of 76% (90% CI, 67.3 to 83.3) in the entire cohort, and 72% and 79% in the myeloablative and reduced-intensity conditioning strata, respectively. Secondary end points related to engraftment and graft-versus-host-disease were reached. Multivariate analysis comparing the study group with other mismatched HCT controls found no significant differences in OS.ConclusionOur prospective study demonstrates the feasibility and effectiveness of HCT with an MMUD in the setting of PTCy. Remarkably, nearly half of the study participants belonged to an ethnic minority population, suggesting this approach may significantly expand access to HCT.

Published
2021

30. Association between busulfan exposure and survival in patients undergoing a CD34+ selected stem cell transplantation

Author

Tamari, Roni, Scordo, Michael, Kunvarjee, Binni M., Proli, Anthony, Lin, Andrew, Flynn, Jessica, Cho, Christina, Devlin, Sean, Klein, Elizabeth, Boulad, Farid, Cancio, Maria I., Curran, Kevin J., Jakubowski, Ann A., Kernan, Nancy A., Kung, Andrew L., O’Reilly, Richard J., Papadopoulos, Esperanza B., Prockop, Susan, Scaradavou, Andromachi, Shaffer, Brian C., Shah, Gunjan, Spitzer, Barbara, Gyurkocza, Boglarka, Giralt, Sergio A., Perales, Miguel-Angel, and Boelens, Jaap Jan

Published
2023
Full Text
View/download PDF

31. Analysis of disparities in time to allogeneic transplantation in adults with acute myelogenous leukemia

Author

Fingrut, Warren B., Gyurkocza, Boglarka, Flynn, Jessica, Davis, Eric, Devlin, Sean, Scaradavou, Andromachi, Chinapen, Stephanie, Quach, Sean, Cho, Christina, Giralt, Sergio A., Jakubowski, Ann A., Lin, Richard J., Papadopoulos, Esperanza B., Perales, Miguel-Angel, Ponce, Doris, Shaffer, Brian C., Tamari, Roni, Young, James W., Politikos, Ioannis, and Barker, Juliet N.

Published
2023
Full Text
View/download PDF

33. Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis following mismatched unrelated donor peripheral blood stem cell (PBSC) transplantation.

Author

Al Malki, Monzr M., primary, Bo-Subait, Stephanie, additional, Logan, Brent, additional, Olson, Janelle, additional, Leckrone, Erin, additional, Wu, Juan, additional, Stefanski, Heather E., additional, Auletta, Jeffery J., additional, Spellman, Stephen R., additional, Malmberg, Craig, additional, Shaffer, Brian C., additional, Modi, Dipenkumar, additional, Khimani, Farhad, additional, Gooptu, Mahasweta, additional, Hamadani, Mehdi, additional, Broglie, Larisa, additional, Shaw, Bronwen E., additional, Devine, Steven Michael, additional, and Jimenez Jimenez, Antonio Martin, additional

Published
2024
Full Text
View/download PDF

34. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission.

Author

Rashidi, Armin, Hamadani, Mehdi, Zhang, Mei-Jie, Wang, Hai-Lin, Abdel-Azim, Hisham, Aljurf, Mahmoud, Assal, Amer, Bajel, Ashish, Bashey, Asad, Battiwalla, Minoo, Beitinjaneh, Amer, Bejanyan, Nelli, Bhatt, Vijaya, Bolaños-Meade, Javier, Byrne, Michael, Cahn, Jean-Yves, Cairo, Mitchell, Ciurea, Stefan, Copelan, Edward, Cutler, Corey, Daly, Andrew, Diaz, Miguel-Angel, Farhadfar, Nosha, Gale, Robert, Ganguly, Siddhartha, Grunwald, Michael, Hahn, Theresa, Hashmi, Shahrukh, Hildebrandt, Gerhard, Holland, H, Hossain, Nasheed, Kanakry, Christopher, Kharfan-Dabaja, Mohamed, Khera, Nandita, Koc, Yener, Lazarus, Hillard, Lee, Jong-Wook, Maertens, Johan, Martino, Rodrigo, McGuirk, Joseph, Munker, Reinhold, Murthy, Hemant, Nakamura, Ryotaro, Nathan, Sunita, Nishihori, Taiga, Palmisiano, Neil, Patel, Sagar, Pidala, Joseph, Olin, Rebecca, Olsson, Richard, Oran, Betul, Ringden, Olov, Rizzieri, David, Rowe, Jacob, Savoie, Mary, Schultz, Kirk, Seo, Sachiko, Shaffer, Brian, Singh, Anurag, Solh, Melhem, Stockerl-Goldstein, Keith, Verdonck, Leo, Wagner, John, Waller, Edmund, De Lima, Marcos, Sandmaier, Brenda, Litzow, Mark, Weisdorf, Dan, Romee, Rizwan, and Saber, Wael

Subjects
Adolescent, Adult, Aged, Blood Donors, Bone Marrow Transplantation, Calcineurin Inhibitors, Chronic Disease, Cyclophosphamide, Disease-Free Survival, Female, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Immunosuppressive Agents, Incidence, Leukemia, Myeloid, Acute, Male, Middle Aged, Recurrence, Remission Induction, Retrospective Studies, Siblings, Survival Analysis, Transplantation Conditioning, Transplantation, Haploidentical, Young Adult
Abstract

HLA-haploidentical hematopoietic cell transplantation (Haplo-HCT) using posttransplantation cyclophosphamide (PT-Cy) has improved donor availability. However, a matched sibling donor (MSD) is still considered the optimal donor. Using the Center for International Blood and Marrow Transplant Research database, we compared outcomes after Haplo-HCT vs MSD in patients with acute myeloid leukemia (AML) in first complete remission (CR1). Data from 1205 adult CR1 AML patients (2008-2015) were analyzed. A total of 336 patients underwent PT-Cy-based Haplo-HCT and 869 underwent MSD using calcineurin inhibitor-based graft-versus-host disease (GVHD) prophylaxis. The Haplo-HCT group included more reduced-intensity conditioning (65% vs 30%) and bone marrow grafts (62% vs 7%), consistent with current practice. In multivariable analysis, Haplo-HCT and MSD groups were not different with regard to overall survival (P = .15), leukemia-free survival (P = .50), nonrelapse mortality (P = .16), relapse (P = .90), or grade II-IV acute GVHD (P = .98). However, the Haplo-HCT group had a significantly lower rate of chronic GVHD (hazard ratio, 0.38; 95% confidence interval, 0.30-0.48; P < .001). Results of subgroup analyses by conditioning intensity and graft source suggested that the reduced incidence of chronic GVHD in Haplo-HCT is not limited to a specific graft source or conditioning intensity. Center effect and minimal residual disease-donor type interaction were not predictors of outcome. Our results indicate a lower rate of chronic GVHD after PT-Cy-based Haplo-HCT vs MSD using calcineurin inhibitor-based GVHD prophylaxis, but similar other outcomes, in patients with AML in CR1. Haplo-HCT is a viable alternative to MSD in these patients.

Published
2019

36. The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT

Author

Shouval, Roni, Fein, Joshua A., Cho, Christina, Avecilla, Scott T., Ruiz, Josel, Tomas, Ana Alarcon, Sanchez-Escamilla, Miriam, Flores, Nerea Castillo, Yáñez, Lucrecia, Barker, Juliet N., Dahi, Parastoo, Giralt, Sergio A., Geyer, Alexander I., Gyurkocza, Boglarka, Jakubowski, Ann A., Lin, Richard J., O'Reilly, Richard J., Papadopoulos, Esperanza B., Politikos, Ioannis, Ponce, Doris M., Sauter, Craig S., Scordo, Michael, Shaffer, Brian, Shah, Gunjan L., Sullivan, James P., Tamari, Roni, van den Brink, Marcel R.M., Young, James W., Nagler, Arnon, Devlin, Sean, Shimoni, Avichai, and Perales, Miguel-Angel

Published
2022
Full Text
View/download PDF

37. Post-Transplant Cyclophosphamide–Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors.

Author

Shaffer, Brian C., Gooptu, Mahasweta, DeFor, Todd E., Maiers, Martin, Bolaños-Meade, Javier, Abboud, Ramzi, Briggs, Adrienne D., Khimani, Farhad, Modi, Dipenkumar, Newcomb, Richard, Shpall, Elizabeth J., Bupp, Caitrin, Spellman, Stephen R., Stefanski, Heather E., Shaw, Bronwen E., Auletta, Jeffery J., Devine, Steven M., Jimenez Jimenez, Antonio M., and Al Malki, Monzr M.

Published
2024
Full Text
View/download PDF

38. Antithymocyte globulin exposure in CD34+ T-cell–depleted allogeneic hematopoietic cell transplantation

Author

Lakkaraja, Madhavi, Scordo, Michael, Mauguen, Audrey, Cho, Christina, Devlin, Sean, Ruiz, Josel D., Klein, Elizabeth, Avecilla, Scott T., Boulad, Farid, Cancio, Maria I., Curran, Kevin J., Jakubowski, Ann A., Kernan, Nancy A., Kung, Andrew L., O'Reilly, Richard J., Papadopoulos, Esperanza B., Prockop, Susan, van Roessel, Ichelle, Scaradavou, Andromachi, Shaffer, Brian C., Shah, Gunjan, Spitzer, Barbara, Tamari, Roni, Giralt, Sergio A., Perales, Miguel-Angel, and Boelens, Jaap Jan

Published
2022
Full Text
View/download PDF

39. High-dose Alemtuzumab-Cyclosporine vs Tacrolimus-Methotrexate-Sirolimus for Chronic Graft-versus-Host Disease Prevention

Author

Holtzman, Noa G., primary, Curtis, Lauren M, additional, Salit, Rachel B, additional, Shaffer, Brian C, additional, Pirsl, Filip, additional, Ostojic, Alen, additional, Steinberg, Seth M, additional, Schulz, Eduard, additional, Wilder, Jennifer S., additional, Hughes, Thomas E, additional, Rose, Jeremy, additional, Memon, Sarfraz, additional, Korngold, Robert, additional, Gea-Banacloche, Juan, additional, Fowler, Daniel H, additional, Hakim, Frances T, additional, Gress, Ronald E., additional, Bishop, Michael R., additional, and Pavletic, Steven Z, additional

Published
2024
Full Text
View/download PDF

40. Racial/ ethnic disparities in availability of volunteer unrelated donors for allogeneic transplantation

Author

Fingrut, Warren B, primary, Davis, Eric, additional, Archer, Anne, additional, Brown, Samantha, additional, Devlin, Sean M., additional, Nhaissi, Melissa, additional, Rapoport, Candice, additional, Chinapen, Stephanie, additional, Kelly, Amanda, additional, Wells, Deborah S, additional, Scaradavou, Andromachi, additional, Gyurkocza, Boglarka, additional, Papadopoulos, Esperanza B., additional, Politikos, Ioannis, additional, Shaffer, Brian C, additional, and Barker, Juliet, additional

Published
2024
Full Text
View/download PDF

43. KIR3DL1/HLA-B Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation

Author

Boudreau, Jeanette E, Giglio, Fabio, Gooley, Ted A, Stevenson, Philip A, Le Luduec, Jean-Benoît, Shaffer, Brian C, Rajalingam, Raja, Hou, Lihua, Hurley, Carolyn Katovich, Noreen, Harriet, Reed, Elaine F, Yu, Neng, Vierra-Green, Cynthia, Haagenson, Michael, Malkki, Mari, Petersdorf, Effie W, Spellman, Stephen, and Hsu, Katharine C

Subjects
Cancer, Pediatric, Pediatric Cancer, Rare Diseases, Stem Cell Research, Stem Cell Research - Nonembryonic - Human, Transplantation, Childhood Leukemia, Clinical Research, Hematology, 2.1 Biological and endogenous factors, Aetiology, Adolescent, Adult, Aged, Alleles, Cell Line, Child, Child, Preschool, Cytotoxicity Tests, Immunologic, Female, Genetic Variation, Genotype, HLA-B Antigens, Hematopoietic Stem Cell Transplantation, Humans, Infant, Infant, Newborn, Killer Cells, Natural, Leukemia, Myeloid, Acute, Male, Middle Aged, Receptors, KIR, Receptors, KIR3DL1, Recurrence, Survival Rate, Transplantation, Homologous, Young Adult, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Purpose Disease relapse remains a major challenge to successful outcomes in patients who undergo allogeneic hematopoietic cell transplantation (HCT). Donor natural killer (NK) cell alloreactivity in HCT can control leukemic relapse, but capturing alloreactivity in HLA-matched HCT has been elusive. HLA expression on leukemia cells-upregulated in the post-HCT environment-signals for NK cell inhibition via inhibitory killer immunoglobulin-like (KIR) receptors and interrupts their antitumor activity. We hypothesized that varied strengths of inhibition among subtypes of the ubiquitous KIR3DL1 and its cognate ligand, HLA-B, would titrate NK reactivity against acute myelogenous leukemia (AML). Patients and Methods By using an algorithm that was based on polymorphism-driven expression levels and specificities, we predicted and tested inhibitory and cytotoxic NK potential on the basis of KIR3DL1/HLA-B subtype combinations in vitro and evaluated their impact in 1,328 patients with AML who underwent HCT from 9/10 or 10/10 HLA-matched unrelated donors. Results Segregated by KIR3DL1 subtype, NK cells demonstrated reproducible patterns of strong, weak, or noninhibition by target cells with defined HLA-B subtypes, which translated into discrete cytotoxic hierarchies against AML. In patients, KIR3DL1 and HLA-B subtype combinations that were predictive of weak inhibition or noninhibition were associated with significantly lower relapse (hazard ratio [HR], 0.72; P = .004) and overall mortality (HR, 0.84; P = .030) compared with strong inhibition combinations. The greatest effects were evident in the high-risk group of patients with all KIR ligands (relapse: HR, 0.54; P < .001; and mortality: HR, 0.74; P < .008). Beneficial effects of weak and noninhibiting KIR3DL1 and HLA-B subtype combinations were separate from and additive to the benefit of donor activating KIR2DS1. Conclusion Consideration of KIR3DL1-mediated inhibition in donor selection for HLA-matched HCT may achieve superior graft versus leukemia effects, lower risk for relapse, and an increase in survival among patients with AML.

Published
2017

44. High progression-free survival after intermediate intensity double unit cord blood transplantation in adults

Author

Barker, Juliet N., Devlin, Sean M., Naputo, Kristine A., Skinner, Kelcey, Maloy, Molly A., Flynn, Lisa, Anagnostou, Theodora, Avecilla, Scott T., Scaradavou, Andromachi, Cho, Christina, Dahi, Parastoo B., Giralt, Sergio A., Gyurkocza, Boglarka, Hanash, Alan M., Hsu, Katharine, Jakubowski, Ann A., Papadopoulos, Esperanza B., Peled, Jonathan U., Perales, Miguel-Angel, Sauter, Craig S., Shah, Gunjan L., Shaffer, Brian C., Tamari, Roni, Young, James W., Roshal, Mikhail, O'Reilly, Richard J., Ponce, Doris M., and Politikos, Ioannis

Published
2020
Full Text
View/download PDF

45. Prognostic Factors for Postrelapse Survival after ex Vivo CD34+-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma

Author

Gomez-Arteaga, Alexandra, Shah, Gunjan L., Baser, Raymond E., Scordo, Michael, Ruiz, Josel D., Bryant, Adam, Dahi, Parastoo B., Ghosh, Arnab, Lahoud, Oscar B., Landau, Heather J., Landgren, Ola, Shaffer, Brian C., Smith, Eric L., Koehne, Guenther, Perales, Miguel-Angel, Giralt, Sergio A., and Chung, David J.

Published
2020
Full Text
View/download PDF

48. Ex Vivo T Cell-Depleted Hematopoietic Stem Cell Transplantation for Adult Patients with Acute Myelogenous Leukemia in First and Second Remission: Long-Term Disease-Free Survival with a Significantly Reduced Risk of Graft-versus-Host Disease

Author

Montoro, Juan, Ceberio, Izaskun, Hilden, Patrick, Maloy, Molly A., Barker, Juliet, Castro-Malaspina, Hugo, Dahi, Parastoo, Koehne, Guenther, Perales, Miguel-Angel, Ponce, Doris, Sauter, Craig, Shaffer, Brian, Tamari, Roni, Young, James W., Giralt, Sergio A., O'Reilly, Richard J., Jakubowski, Ann A., and Papadopoulos, Esperanza B.

Published
2020
Full Text
View/download PDF

49. Phase 2 Trial of Ruxolitinib Cream for Chronic Cutaneous GvHD

Author

Markova, Alina, primary, Papadopoulos, Esperanza B., additional, Dusza, Stephen, additional, Rotemberg, Veronica, additional, Ostojic, Jelena, additional, Ai, Rizi, additional, Maier, Tara, additional, Lacouture, Mario E., additional, Tamari, Roni, additional, Gyurkocza, Boglarka, additional, Shaffer, Brian C., additional, Scordo, Michael, additional, Perales, Miguel-Angel, additional, Harris, Andrew C., additional, and Ponce, Doris M., additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results